La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Neuren Pharmaceuticals Gestion
Gestion contrôle des critères 0/4
Informations clés
Jon Pilcher
Directeur général
AU$1.4m
Rémunération totale
Pourcentage du salaire du PDG | 40.2% |
Durée du mandat du directeur général | 4.3yrs |
Propriété du PDG | 0.3% |
Durée moyenne d'occupation des postes de direction | 4.1yrs |
Durée moyenne du mandat des membres du conseil d'administration | 6.1yrs |
Mises à jour récentes de la gestion
Recent updates
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04Analyse de la rémunération des PDG
Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
---|---|---|---|
Dec 31 2023 | AU$1m | AU$549k | AU$157m |
Sep 30 2023 | n/a | n/a | AU$106m |
Jun 30 2023 | n/a | n/a | AU$55m |
Mar 31 2023 | n/a | n/a | AU$28m |
Dec 31 2022 | AU$546k | AU$396k | AU$184k |
Sep 30 2022 | n/a | n/a | -AU$3m |
Jun 30 2022 | n/a | n/a | -AU$7m |
Mar 31 2022 | n/a | n/a | -AU$7m |
Dec 31 2021 | AU$432k | AU$203k | -AU$8m |
PDG
Jon Pilcher
4.3yrs
Titularisation
AU$1,364,404
Compensation
Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...
Équipe de direction
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
CEO, MD & Executive Director | 4.3yrs | AU$1.36m | 0.31% A$ 6.1m | |
CFO & Company Secretary | 4yrs | pas de données | pas de données | |
Chief Science Officer | 20.6yrs | pas de données | pas de données | |
Vice President of Corporate Development | no data | pas de données | pas de données | |
Chief Medical Officer | 2.1yrs | pas de données | pas de données |
4.1yrs
Durée moyenne de l'emploi
Membres du conseil d'administration
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
CEO, MD & Executive Director | 3.2yrs | AU$1.36m | 0.31% A$ 6.1m | |
Independent Non-Executive Director | 6.1yrs | AU$75.00k | 0.023% A$ 459.6k | |
Independent Non-Executive Director | 6.1yrs | AU$75.00k | 0.023% A$ 454.5k | |
Independent Non-Executive Chairman | 6.1yrs | AU$125.00k | 0.21% A$ 4.1m | |
Independent Non-Executive Director | 1.4yrs | AU$62.50k | 0.017% A$ 328.0k |
6.1yrs